Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Applied Molecular Transport reports Q3 EPS (48c), consensus (41c) » 16:31
11/12/20
11/12
16:31
11/12/20
16:31
AMTI

Applied Molecular Transport

$29.23 /

-1.18 (-3.88%)

As of September 30, cash,…

As of September 30, cash, cash equivalents, and investments were $147.3M. "We continue to make important progress in the development of our differentiated oral biologic drug candidates in a number of indications," said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. "We recently advanced oral AMT-101 into a Phase 2 monotherapy trial in patients with ulcerative colitis (UC). In addition, we continue the planned expansion of this comprehensive clinical program with two additional Phase 2 trials of AMT-101 in combination with anti-TNFa therapy in biologic-naive patients with moderate to severe UC and as a monotherapy in patients with pouchitis, both initiating by year-end. We are also looking forward to the initiation of the fourth Phase 2 trial for AMT-101 in combination with anti-TNFa in rheumatoid arthritis patients who are partially responding to anti-TNFa therapy. Furthermore, given the broad potential of our technology platform as an engine for the development of novel oral biologics, we continue to work on expanding our deep pipeline into additional indications and therapeutic areas and look forward to sharing updates on our progress."

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$29.23 /

-1.18 (-3.88%)

AMTI Applied Molecular Transport
$29.23 /

-1.18 (-3.88%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
AMTI Applied Molecular Transport
$29.23 /

-1.18 (-3.88%)

  • 05
    Jun
AMTI Applied Molecular Transport
$29.23 /

-1.18 (-3.88%)

Hot Stocks
Applied Molecular reports publication of preclinical data on AMT-101 » 08:10
11/10/20
11/10
08:10
11/10/20
08:10
AMTI

Applied Molecular Transport

$30.26 /

+0.37 (+1.24%)

Applied Molecular…

Applied Molecular Transport announced that the unique mechanism of action of AMT-101 and preclinical data supporting its potential as a treatment for ulcerative colitis, and other inflammatory diseases, have been published in The Journal of Immunology. The article entitled, "A Novel Fusion of Interleukin-10 Engineered to Traffic Across Intestinal Epithelium to Treat Colitis" was published in the November 2020 online edition of The Journal of Immunology. The research published in The Journal of Immunology highlights how AMT's proprietary technology platform exploits existing natural cellular trafficking pathways to actively transport therapeutics through the intestinal barrier directly into the underlying immune-rich milieu of the lamina propria. IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation. However, clinical utilization of IL-10 to treat inflammation and immune-dysregulation has been limited due to side effects associated with systemic administration.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$30.26 /

+0.37 (+1.24%)

AMTI Applied Molecular Transport
$30.26 /

+0.37 (+1.24%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
AMTI Applied Molecular Transport
$30.26 /

+0.37 (+1.24%)

  • 05
    Jun
AMTI Applied Molecular Transport
$30.26 /

+0.37 (+1.24%)

Conference/Events
Applied Molecular Transport management to meet virtually with JMP Securities » 04:55
10/30/20
10/30
04:55
10/30/20
04:55
AMTI

Applied Molecular Transport

$30.95 /

-0.9 (-2.83%)

Virtual Meeting to be…

Virtual Meeting to be held on October 30 hosted by JMP Securities.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$30.95 /

-0.9 (-2.83%)

AMTI Applied Molecular Transport
$30.95 /

-0.9 (-2.83%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
AMTI Applied Molecular Transport
$30.95 /

-0.9 (-2.83%)

  • 05
    Jun
AMTI Applied Molecular Transport
$30.95 /

-0.9 (-2.83%)

Over a month ago
Conference/Events
Applied Molecular Transport management to meet virtually with JMP Securities » 11:08
10/26/20
10/26
11:08
10/26/20
11:08
AMTI

Applied Molecular Transport

$32.49 /

+0.54 (+1.69%)

Virtual Meeting to be…

Virtual Meeting to be held on October 30 hosted by JMP Securities.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$32.49 /

+0.54 (+1.69%)

AMTI Applied Molecular Transport
$32.49 /

+0.54 (+1.69%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
AMTI Applied Molecular Transport
$32.49 /

+0.54 (+1.69%)

  • 05
    Jun
AMTI Applied Molecular Transport
$32.49 /

+0.54 (+1.69%)

Over a quarter ago
Hot Stocks
Applied Molecular Transport doses first patient in Phase 2 study in AMT-101 » 08:17
08/27/20
08/27
08:17
08/27/20
08:17
AMTI

Applied Molecular Transport

$21.00 /

+ (+0.00%)

Applied Molecular…

Applied Molecular Transport announced that the first patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severely active ulcerative colitis. AMT-101 is a gut-selective, oral, once-daily, biologic fusion protein of interleukin 10 which utilizes the company's proprietary platform technology to harness the power of natural active transport mechanisms for a potentially more efficacious and safer biologic therapeutic. The Phase 2a study will include approximately 100 adult patients with moderate to severely active UC who will be randomized 2:1 to either receive oral AMT-101 or placebo for 12 weeks of treatment. The global study will enroll both biologic-experienced and naive patients in approximately 20 countries. The primary endpoint of the study is to assess the efficacy of repeat oral doses of AMT-101 versus placebo in reducing components of the Mayo Score at week 12. Secondary endpoints include safety, pharmacokinetics, health-related quality of life, and markers of disease activity as measured by symptoms, endoscopy, histology, and biomarkers. Exploratory objectives include assessments of the pharmacodynamic effect on inflammation and biomarkers, as well as PK parameters in mucosal tissue.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$21.00 /

+ (+0.00%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
AMTI Applied Molecular Transport
$21.00 /

+ (+0.00%)

  • 05
    Jun
AMTI Applied Molecular Transport
$21.00 /

+ (+0.00%)

Earnings
Applied Molecular Transport reports Q2 EPS ($1.11), consensus (38c) » 16:02
08/11/20
08/11
16:02
08/11/20
16:02
AMTI

Applied Molecular Transport

$21.54 /

-0.09 (-0.42%)

As of June 30, 2020,…

As of June 30, 2020, cash, cash equivalents, and investments were $163.3 million, compared to $32.7 million as of December 31, 2019. The increase was primarily driven by the company's initial public offering in June of this year. "As we expected, 2020 has been a transformational year with the successful execution of our initial public offering, the appointment of key executives, the generation of important clinical data for our lead product candidate AMT-101, and the advancement of AMT-101 into a comprehensive Phase 2 clinical program during the second half of this year," said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. "The AMT-101 Phase 1a/b clinical data are a compelling validation of our technology platform as an engine for developing differentiated oral biologics product candidates including peptides, proteins, antibodies and RNA therapeutics."

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$21.54 /

-0.09 (-0.42%)

06/30/20 SVB Leerink
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform
06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
  • 05
    Jun
AMTI Applied Molecular Transport
$21.54 /

-0.09 (-0.42%)

Initiation
SVB Leerink bullish on Applied Molecular Transport, initiates with Outperform » 09:02
06/30/20
06/30
09:02
06/30/20
09:02
AMTI

Applied Molecular Transport

$25.11 /

-1.12 (-4.27%)

As previously reported,…

As previously reported, SVB Leerink analyst Joseph Schwartz initiated coverage of Applied Molecular Transport with an Outperform rating and $32 price target. The analyst believes the company's emerging translocation mucosal delivery platform may enable new ways to treat patients with autoimmune diseases which present significant unmet medical need despite several approved drugs. If validated in these lead indications, he thinks the platform could garner more credit due to the potential versatility of its active transport system, which could enable the long sought-after ability to deliver biologics through oral administration.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

06/30/20 Jefferies
Applied Molecular Transport initiated with a Buy at Jefferies
06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
  • 05
    Jun
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

Initiation
Applied Molecular Transport initiated with a Buy at Jefferies » 07:50
06/30/20
06/30
07:50
06/30/20
07:50
AMTI

Applied Molecular Transport

$25.11 /

-1.12 (-4.27%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Applied Molecular Transport with a Buy rating and $38 price target. The company's lead program, AMT-101, has him "excited by the early signs of efficacy and safety" while its platform could present "multi-billion dollar opportunities" across inflammatory bowel disease and potentially many other therapeutic areas, Howerton tells investors.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

06/30/20 SVB Leerink
Applied Molecular Transport initiated with an Outperform at SVB Leerink
06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
  • 05
    Jun
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

Initiation
Applied Molecular Transport initiated with an Outperform at SVB Leerink » 06:53
06/30/20
06/30
06:53
06/30/20
06:53
AMTI

Applied Molecular Transport

$25.11 /

-1.12 (-4.27%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz initiated coverage of Applied Molecular Transport with an Outperform rating and $32 price target.

ShowHide Related Items >><<
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

06/30/20 BofA
Applied Molecular Transport initiated with a Buy at BofA
  • 05
    Jun
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

Initiation
Applied Molecular Transport initiated with a Buy at BofA » 06:27
06/30/20
06/30
06:27
06/30/20
06:27
AMTI

Applied Molecular Transport

$25.11 /

-1.12 (-4.27%)

BofA analyst Jason…

BofA analyst Jason Gerberry initiated coverage of Applied Molecular Transport with a Buy rating and $34 price target. The analyst is positive on the company's protein carrier technology as being "unique in exploiting natural cellular trafficking pathways to facilitate oral absorption of biologics", which historically has been an industry challenge since "bulky proteins cannot efficiently cross the gut wall." Gerberry adds that Applied Molecular has "multiple shots on goals" with its lead asset AMT-101, stating that he is also impressed with its ability to safely induce histologic disease normalization in patients with ulcerative colitis.

ShowHide Related Items >><<
  • 05
    Jun
AMTI Applied Molecular Transport
$25.11 /

-1.12 (-4.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.